IM
IMUC.US ImmunoCellular Therapeutics Ltd
- Market cap
- USD 20.0M
- P/E
- 0.1x
- P/B
- 0.35x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is IMUC.US undervalued?
Graham numberThe Graham number of ImmunoCellular Therapeutics Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ImmunoCellular Therapeutics Ltd fundamental analysis
No fundamental analysis for ImmunoCellular Therapeutics Ltd yet.
ImmunoCellular Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ImmunoCellular Therapeutics Ltd
EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company's lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer…
Full company profileImmunoCellular Therapeutics Ltd financial statements
ImmunoCellular Therapeutics Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - |
| Gross Profit | -47.7K | -36.2K | -75.1K | -47.8K | - | - | - | - | - | - |
| Operating Income | -9.86M | -15.5M | -24.1M | -21.2M | -1.45M | -2.61M | -2.89M | -1.65M | -2.01M | -1.83M |
| EBITDA | -9.33M | -12.5M | -20.2M | -13.4M | -1.45M | -1.00 | -2.21M | -999K | -929K | -1.83M |
| Net Income | -9.39M | -12.9M | -23.4M | -18.5M | -1.45M | -2.68M | -2.65M | -1.61M | -1.89M | -1.92M |
| EPS | -64 | -59 | -84 | -4.42 | -0.03 | -0.06 | -0.02 | -0.01 | -0.02 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 25.2M | 30.1M | 16.9M | 7.01M | 267K | 1.67M | 769K | 409K | 390K | 99.5K |
| Total Liabilities | 1.89M | 8.36M | 10.8M | 2.36M | 137K | 3.28M | 4.96M | 6.10M | 1.01M | 2.49M |
| Shareholders' Equity | 23.3M | 21.7M | 6.13M | 4.65M | 130K | -1.62M | -4.19M | -5.69M | -618K | -2.39M |
| Cash & Short-term Investments | 23.2M | 22.6M | 11.4M | 6.63M | 263K | 1.49M | 613K | 278K | 98.7K | 29.8K |
| Total Debt | - | - | - | - | - | 2.82M | 3.47M | 4.74M | 442K | 1.76M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -9.94M | -19.0M | -19.9M | -16.7M | -1.24M | -2.31M | -2.62M | -1.42M | -2.68M | -1.49M |
| Capital Expenditure | 29.0K | 170K | 4.02K | 0.00 | 0.00 | 5.00 | 0.00 | 4.00 | 5.00 | 3.00 |
| Free Cash Flow | -9.97M | -19.2M | -19.9M | -16.7M | -1.24M | -2.31M | -2.62M | -1.42M | -2.68M | -1.49M |
| Ratios | ||||||||||
| ROE | -40.3% | -59.5% | -381.6% | -398.3% | -1,121.3% | - | - | - | - | - |
| ROA | -37.3% | -43.0% | -138.5% | -264.2% | -544.8% | -160.8% | -344.3% | -393.9% | -485.6% | -1,933.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
ImmunoCellular Therapeutics Ltd dividends
ImmunoCellular Therapeutics Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 1:10 on Sep 16, 2020.
Who owns ImmunoCellular Therapeutics Ltd
- Insiders 94.97%
- Institutions 0.00%
- Public & others 5.03%
- Shares outstanding 127M
- Free float 5.70M
ImmunoCellular Therapeutics Ltd company profile
- Company name
- ImmunoCellular Therapeutics Ltd
- Ticker
- IMUC.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- 136 Summit Avenue, Montvale, NJ, United States, 07645
- Phone
- 201 351 0605
- Website
- eompharma.com
About ImmunoCellular Therapeutics Ltd
EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company's lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis, as well as in Phase ½ a clinical trial to treat infectious diseases, such as COVID-19. It also develops EOM 147, an investigational broad-spectrum aminosterol with an intracellular mechanism that has completed Phase 2 clinical trial for the treatment of age-related macular degeneration, diabetic retinopathy, and macular edema due to retinal vain occlusion. EOM Pharmaceuticals Holdings, Inc. was founded in 2020 and is headquartered in Montvale, New Jersey.
ImmunoCellular Therapeutics Ltd management
4- Dr. Irach B. Taraporewala B.S., M.S., Ph.D.CEO, President & Director · born 1956
- Mr. Wayne I. Danson CPACFO & Treasurer · born 1954
- Mr. Eli GoldbergerFounder, Chairman & COO · born 1991
- Dr. Shalom Z. Hirschman M.D.Co-Founder, Chief Scientific Officer & Medical Director · born 1936